*November 2020*

Alexander Spira, MD, PhD, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the phase 1 CHRYSALIS trial of amivantamab (JNJ-61186372) plus lazertinib (YH25448) in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.

In the relapsed/refractory population, there was about a 36% or 37% response rate, with significantly more patients benefiting. This is good because it’s designed as a non-chemotherapy option since chemotherapy would be the normal approach for these patients, according to Spira. Since the proof of concept worked, there is potential for a non-chemotherapy option in this setting. Read more.